Страна: Малайзия
Език: английски
Източник: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
LOVASTATIN
DUOPHARMA (M) SDN. BHD.
LOVASTATIN
100 Tablets; 250 Tablets; 500 Tablets
DUOPHARMA (M) SDN. BHD.
Page 1 of 1 [REVISION DATE: 24.07.2019] [DUOPHARMA (M) SDN BHD] LOVANCO TABLET DESCRIPTION: LOVANCO TABLET is a round scored tablet, white in colour with markings “DUO 2” and a “Flower”. COMPOSITION: Each tablet contains Lovastatin 20 mg. PHARMACODYNAMICS: Lovastatin which has been isolated from Aspergillus terreus, is a hypolipidaemic agent; it is a competitive inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMG-CoA reductase), the rate-determining enzyme for cholesterol synthesis. Lovastatin reduces total and low-density lipoprotein (LDL)-Cholesterol and very low density lipoprotein (VLDL)-cholesterol. It tends to reduce triglycerides and to increase high-density lipoprotein concentrations. Lovastatin and the other HMG-CoA reductase inhibitors are considered to exert their hypocholesterolaemic action by stimulating and increase in LDL-receptors on hepatocyte membranes thereby increasing the clearance of LDL from the circulation. PHARMACOKINETICS: Lovastatin is absorbed from the gastro-intestinal tract and is hydrolysed in the liver to its active β-hydroxyacid form. Three other metabolites have also been isolated. Lovastatin undergoes extensive first- pass extraction in the liver, its primary site of action, and less than 5% of the oral dose has been reported to reach the circulation. Peak plasma concentrations occur within 2 to 4 hours, and steady state concentrations are achieved after 2 to 3 days with daily administration. Both lovastatin and its β-hydroxyacid metabolite are extensively bound to plasma proteins. It is mainly excreted in the bile about 85% of the administered dose has been recovered from the faeces and about 10% from the urine. Lovastatin has been shown to be effective in uncomplicated, well-controlled insulin dependent (Type 1) and non-insulin dependent (Type 2) diabetic patients with primary hypercholesterolemia. Reduction of plasma metabolites are extensively bound to plasma proteins. It is mainly excreted in the bile about 85% of the administered dose has been recove Прочетете целия документ